Neurobehavioral aspects, pathophysiology, and management of Tourette syndrome

Current Opinion in Neurology

Volumn 27, Issue 4, 2014, Pages 484-492

  Shprecher, David R ^a   Schrock, Lauren ^a   Himle, Michael ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

attention deficit hyperactivity disorder; comprehensive behavioral intervention for tics; deep brain stimulation; MRI; obsessive compulsive disorder; tic; Tourette syndrome

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CANNABINOID; DOPAMINE DEPLETING AGENT; DOPAMINE RECEPTOR AFFECTING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; ECOPIPAM; FLUPHENAZINE; HALOPERIDOL; PIMOZIDE; RISPERIDONE; TETRABENAZINE; TIAPRIDE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; ALCOHOL DEHYDROGENASE; BENZAZEPINE DERIVATIVE; HISTIDINOL DEHYDROGENASE; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ATTENTION DEFICIT DISORDER; AUTOIMMUNE DISEASE; BEHAVIOR THERAPY; BRAIN DEPTH STIMULATION; BRAIN SURGERY; COGNITION; COMORBIDITY; COPY NUMBER VARIATION; ENVIRONMENTAL ASPECTS AND RELATED PHENOMENA; GENETICS; GILLES DE LA TOURETTE SYNDROME; HUMAN; IMPULSIVENESS; META ANALYSIS (TOPIC); NEUROIMAGING; NEUROPHYSIOLOGY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); RAGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CEREBELLUM NUCLEUS; COMPLICATION; DISEASE MANAGEMENT; MENTAL DISORDERS; MUTATION; PATHOLOGY; TOURETTE SYNDROME;

ALCOHOL OXIDOREDUCTASES; BENZAZEPINES; CEREBELLAR NUCLEI; DISEASE MANAGEMENT; DOPAMINE ANTAGONISTS; HUMANS; MENTAL DISORDERS; MUTATION; PIPERAZINES; QUINOLONES; TOURETTE SYNDROME;

EID: 84904050261     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000119     Document Type: Review

References (85)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Arlington, VA: American Psychiatric Publishing Inc.; 2013.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Washington DC: American Psychiatric Publishing Inc.; 2000.
3. Knight T, Steeves T, Day L, et al. Prevalence of tic disorders: a systematic review and meta-analysis. Pediatr Neurol 2012; 47:77-90.
4. Cavanna AE, David K, Bandera V, et al. Health-related quality of life in Gilles de la Tourette syndrome: a decade of research. Behav Neurol 2013; 27:83-93.
5. Conelea CA, Busch AM, Catanzaro MA, Budman CL. Tic-related activity restriction as a predictor of emotional functioning and quality of life. Compr Psychiatry 2014; 55:123-129.
6. Wadman R, Tischler V, Jackson GM. 'Everybody just thinks I'm weird': a qualitative exploration of the psychosocial experiences of adolescents with Tourette syndrome. Child Care Health Dev 2013; 39:880-886.
7. Patel N, Jankovic J, Hallett M. Sensory aspects of movement disorders. Lancet Neurol 2014; 13:100-112.
8. Cavanna AE, Nani A. Tourette syndrome and consciousness of action. Tremor Other Hyperkinet Mov (N Y) 2013; 3.
9. Eddy CM, Cavanna AE. Premonitory urges in adults with complicated and uncomplicated Tourette syndrome. Behav Modif 2013. [Epub ahead of print]
10. Crossley E, Cavanna AE. Sensory phenomena: clinical correlates and impact on quality of life in adult patients with Tourette syndrome. Psychiatry Res 2013; 209:705-710.
11. Neal M, Cavanna AE. 'Not just right experiences' in patients with Tourette syndrome: complex motor tics or compulsions? Psychiatry Res 2013; 210:559-563.
12. Neal M, Cavanna AE. Selective sound sensitivity syndrome (misophonia) in a patient with Tourette syndrome. J Neuropsychiatry Clin Neurosci 2013; 25:E01.
13. Cavanna AE, Rickards H. The psychopathological spectrum of Gilles de la Tourette syndrome. Neurosci Biobehav Rev 2013; 37:1008-1015.
14. Scharf JM, Miller LL, Mathews CA, Ben-Shlomo Y. Prevalence of Tourette syndrome and chronic tics in the population-based Avon longitudinal study of parents and children cohort. J Am Acad Child Adolesc Psychiatry 2012; 51:192-201; e5.
15. Eddy CM, Beck SR, Mitchell IJ, et al. Theory of mind deficits in Parkinson's disease: a product of executive dysfunction? Neuropsychology 2013; 27:37-47.
16. Frank MC, Piedad J, Rickards H, Cavanna AE. The role of impulse control disorders in Tourette syndrome: an exploratory study. J Neurol Sci 2011; 310:276-278.
17. Buse J, Schoenefeld K,Munchau A, Roessner V. Neuromodulation in Tourette syndrome: dopamine and beyond. Neurosci Biobehav Rev 2013; 37:1069-1084.
18. Singer HS, Szymanski S, Giuliano J, et al. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry 2002; 159:1329-1336.
19. Wong DF, Brasic JR, Singer HS, et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology 2008; 33: 1239-1251.
20. Denys D, de Vries F, Cath D, et al. Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder. Eur Neuropsychopharmacol 2013; 23:1423-1431.
21. Ganos C, Roessner V, Munchau A. The functional anatomy of Gilles de la Tourette syndrome. Neurosci Biobehav Rev 2013; 37:1050-1062.
22. Bronfeld M, Yael D, Belelovsky K, Bar-Gad I. Motor tics evoked by striatal disinhibition in the rat. Front Syst Neurosci 2013; 7:50.
23. Lerner A, Bagic A, Simmons JM, et al. Widespread abnormality of the gammaaminobutyric acid-ergic system in Tourette syndrome. Brain 2012; 135 (Pt 6):1926-1936.
24. Kataoka Y, Kalanithi PS, Grantz H, et al. Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome. J Comp Neurol 2010; 518:277-291.
25. Swerdlow NR. Update: studies of prepulse inhibition of startle, with particular relevance to the pathophysiology or treatment of Tourette syndrome. Neurosci Biobehav Rev 2013; 37:1150-1156.
26. Rajagopal S, Seri S, Cavanna AE. Premonitory urges and sensorimotor processing in Tourette syndrome. Behav Neurol 2013; 27:65-73.
27. Zebardast N, Crowley MJ, Bloch MH, et al. Brain mechanisms for prepulse inhibition in adults with Tourette syndrome: initial findings. Psychiatry Res 2013; 214:33-41.
28. Paschou P. The genetic basis of Gilles de la Tourette Syndrome. Neurosci Biobehav Rev 2013; 37:1026-1039.
29. Ercan-Sencicek AG, Stillman AA, Ghosh AK, et al. L-histidine decarboxylase and Tourette's syndrome. N Engl J Med 2010; 362:1901-1908.
30. Castellan Baldan L, Williams KA, Gallezot JD, et al. Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humans and mice. Neuron 2014; 81:77-90.
31. Karagiannidis I, Dehning S, Sandor P, et al. Support of the histaminergic hypothesis in Tourette syndrome: association of the histamine decarboxylase gene in a large sample of families. J Med Genet 2013; 50:760-764.
32. Scharf JM, Yu D, Mathews CA, et al. Genome-wide association study of Tourette's syndrome. Mol Psychiatry 2013; 18:721-728.
33. Grayton HM, Fernandes C, Rujescu D, Collier DA. Copy number variations in neurodevelopmental disorders. Prog Neurobiol 2012; 99:81-91.
34. Fernandez TV, Sanders SJ, Yurkiewicz IR, et al. Rare copy number variants in tourette syndrome disrupt genes in histaminergic pathways and overlap with autism. Biol Psychiatry 2012; 71:392-402.
35. Nag A, Bochukova EG, Kremeyer B, et al. CNV analysis in Tourette syndrome implicates large genomic rearrangements in COL8A1 and NRXN1. PLoS One 2013; 8:e59061.
36. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet 2011; 88:76-82.
37. Davis LK, Yu D, Keenan CL, et al. Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet 2013; 9:e1003864.
38. Kurlan R, Johnson D, Kaplan EL. Streptococcal infection and exacerbations of childhood tics and obsessive-compulsive symptoms: a prospective blinded cohort study. Pediatrics 2008; 121:1188-1197.
39. Leckman JF, King RA, Gilbert DL, et al. Streptococcal upper respiratory tract infections and exacerbations of tic and obsessive-compulsive symptoms: a prospective longitudinal study. J Am Acad Child Adolesc Psychiatry 2011; 50:108-118; e3.
40. Morris-Berry CM, Pollard M, Gao S, et al. Antistreptococcal, tubulin, and dopamine receptor 2 antibodies in children with PANDAS and Tourette syndrome: single-point and longitudinal assessments. J Neuroimmunol 2013; 264:106-113.
41. Hornig M, Lipkin WI. Immune-mediated animal models of Tourette syndrome. Neurosci Biobehav Rev 2013; 37:1120-1138.
42. Liu X, Wang X, Li L, et al. Influence of mesenchymal stem cell transplantation on stereotypic behavior and dopamine levels in rats with Tourette syndrome. PLoS One 2013; 8:e62198.
43. Bayhan GI, Tanir G, Ertan U, Bodur S. A case of vocal tic: an unusual presentation of neurobrucellosis. East Mediterr Health J 2013; 19:393-395.
44. Mathews CA, Scharf JM, Miller LL, et al. Association between pre and perinatal exposures and Tourette syndrome or chronic tic disorder in the ALSPAC cohort. Br J Psychiatry 2014; 204:40-45.
45. Miller LL, Scharf JM, Mathews CA, Ben-Shlomo Y. Tourette syndrome and chronic tic disorder are associated with lower socio-economic status: findings from the Avon Longitudinal Study of Parents and Children cohort. Dev Med Child Neurol 2014; 56:157-163.
46. Murphy TK, Lewin AB, Storch EA, Stock S. Practice parameter for the assessment and treatment of children and adolescents with tic disorders. J Am Acad Child Adolesc Psychiatry 2013; 52:1341-1359.
47. Himle MB, Capriotti MR, Hayes LP, et al. Variables associated with tic exacerbation in children with chronic tic disorders. Behav Modif 2014. [Epub ahead of print]
48. Steinberg T, Harush A, Barnea M, et al. Tic-related cognition, sensory phenomena, and anxiety in children and adolescents with Tourette syndrome. Compr Psychiatry 2013; 54:462-466.
49. Reese HE, Scahill L, Peterson AL, et al. The premonitory urge to tic: measurement, characteristics, and correlates in older adolescents and adults. Behav Ther 2014; 45:177-186.
50. Wile DJ, Pringsheim TM. Behavior therapy for Tourette syndrome: a systematic review and meta-analysis. Curr Treat Options in Neurol 2013; 15:385-395.
51. Dutta N, Cavanna AE. The effectiveness of habit reversal therapy in the treatment of Tourette syndrome and other chronic tic disorders: a systematic review. Funct Neurol 2013; 28:7-12.
52. Piacentini J, Woods DW, Scahill L, et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA 2010; 303:1929-1937.
53. Wilhelm S, Peterson AL, Piacentini J, et al. Randomized trial of behavior therapy for adults with Tourette syndrome. Arch Gen Psychiatry 2012; 69:795-803.
54. McGuire JF, Piacentini J, Brennan EA, et al. A meta-analysis of behavior therapy for Tourette syndrome. J Psychiatr Res 2014; 50:106-112.
55. Piacentini J, Bennett SM, Chang S. Behavioral treatment study of comprehensive behavioral intervention for tics in young children. Nashville, TN: Association for Cognitive and Behavioral Therapies; 2013.
56. Scahill L, Woods DW, Himle MB, et al. Current controversies on the role of behavior therapy in Tourette syndrome. Mov Disord 2013; 28:1179-1183.
57. Specht MW, Woods DW, Nicotra CM, et al. Effects of tic suppression: ability to suppress, rebound, negative reinforcement, and habituation to the premonitory urge. Behav Res Ther 2013; 51:24-30.
58. Woods DW, Conelea CC, Himle MB. Behavior therapy for Tourette's disorder: utilization in a community sample and an emerging area of practice for psychologists. Professional Psychol Res Pract 2010; 41:518-525.
59. Himle MB, Freitag M, Walther M, et al. A randomized pilot trial comparing videoconference versus face-to-face delivery of behavior therapy for childhood tic disorders. Behav Res Ther 2012; 50:565-570.
60. Verdellen C, van de Griendt J, Hartmann A, Murphy T. European clinical guidelines for Tourette syndrome and other tic disorders. Part III: behavioural and psychosocial interventions. Eur Child Adolesc Psychiatry 2011; 20:197-207.
61. Pringsheim T, Doja A, Gorman D, et al. Canadian guidelines for the evidencebased treatment of tic disorders: pharmacotherapy. Can J Psychiatry 2012; 57:133-143.
62. Masi G, Pfanner C, Brovedani P. Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study. J Psychiatr Res 2013; 47:1007-1012.
63. Yoo HK, Joung YS, Lee JS, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. J Clin Psychiatry 2013; 74:e772-e780.
64. Otsuka Pharmaceutical Development & Commercialization I. Safety and tolerability of once-daily oral aripiprazole in children and adolescents with Tourette's disorder. Available from: http://clinicaltrials.gov/ct2/show/study/ NCT01727713?term=aripiprazole+tourette&rank=1&show-locs=Y#locn. [Accessed 28 January 2014]
65. Wijemanne S, Wu LJ, Jankovic J. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord 2013; 29:126-130.
66. Muller-Vahl KR, Krueger D. Does Tourette syndrome prevent tardive dyskinesia? Mov Disord 2011; 26:2442-2443.
67. Gilbert DL, Budman CL, Singer HS, et al. A d1 receptor antagonist, ecopipam, for treatment of tics in tourette syndrome. Clin Neuropharmacol 2014; 37:26-30.
68. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007; 22:193-197.
69. Jain S, Greene PE, Frucht SJ. Tetrabenazine therapy of pediatric hyperkinetic movement disorders. Mov Disord 2006; 21:1966-1972.
70. Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 2010; 81:70-73.
71. Yang CS, Zhang LL, Zeng LN, et al. Topiramate for Tourette's syndrome in children: a meta-analysis. Pediatr Neurol 2013; 49:344-350.
72. Ye L, Lippmann S. Tourette disorder treated with valproic acid. Clin Neuropharmacol 2014; 37:36-37.
73. Mü ller-Vahl KR. Treatment of Tourette syndrome with cannabinoids. Behav Neurol 2013; 27:119-124.
74. Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014; 82:1556-1563.
75. Hassler R, Dieckmann G. [Stereotaxic treatment of tics and inarticulate cries or coprolalia considered as motor obsessional phenomena in Gilles de la Tourette's disease]. Rev Neurol (Paris) 1970; 123:89-100.
76. Schrock LE, Woods DW, Porta M, et al. Patient selection and assessment for deep brain stimulation in Tourette syndrome. Mov Disord . (in press).
77. Piedimonte F, Andreani JCM, Piedimonte L, et al. Behavioral and motor improvement after deep brain stimulation of the globus pallidus externus in a case of Tourette's syndrome. Neuromodulation 2013; 16:55-58.
78. Motlagh MG, Smith ME, Landeros-Weisenberger A, et al. Lessons learned from open-label deep brain stimulation for Tourette syndrome: eight cases over 7 years. Tremor Other Hyperkinet Mov (N Y) 2013; 3.
79. Viswanathan A, Jimenez-Shahed J, Baizabal Carvallo JF, Jankovic J. Deep brain stimulation for Tourette syndrome: target selection. Stereotact Funct Neurosurg 2012; 90:213-224.
80. Ackermans L, Duits A, van der Linden C, et al. Double-blind clinical trial of thalamic stimulation in patients with Tourette syndrome. Brain 2011; 134 (Pt 3):832-844.
81. Servello D, Sassi M, Gaeta M, et al. Tourette syndrome (TS) bears a higher rate of inflammatory complications at the implanted hardware in deep brain stimulation (DBS). Acta Neurochir 2011; 153:629-632.
82. Okun MS, Foote KD, Wu SS, et al. A trial of scheduled deep brain stimulation for Tourette syndrome: moving away from continuous deep brain stimulation paradigms. JAMA Neurol 2013; 70:85-94.
83. Maling N, Hashemiyoon R, Foote KD, et al. Increased thalamic gamma band activity correlates with symptom relief following deep brain stimulation in humans with Tourette's syndrome. PLos One 2012; 7:e44215.
84. Cavanna AE, Eddy CM, Mitchell R, et al. An approach to deep brain stimulation for severe treatment-refractory Tourette syndrome: the UK perspective. Br J Neurosurg 2011; 25:38-44.
85. Muller-Vahl KR, Cath DC, Cavanna AE, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part IV: deep brain stimulation. Eur Child Adolesc Psychiatry 2011; 20:209-217.